OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight
Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally.
It is the largest single donation ever made to...
John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director
John C. Byrd, MD, FASCO, an internationally lauded researcher and clinical specialist in hematologic malignancies, has been appointed Director of UPMC Hillman Cancer Center, effective November 2025.
In his role as Director, Dr. Byrd will be responsible for all aspects of the University of...
Cannabis Use Disorder and Risk of Oral Cancer
Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings from a multicenter clinical cohort analysis published in Preventive Medicine Reports.
“Cannabis...
Glioblastoma: Dual Immunotherapy Plus Radiotherapy in Newly Diagnosed MGMT-Unmethylated Disease
The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with radiation therapy and temozolomide for patients with newly diagnosed MGMT-unmethylated glioblastoma, according to phase II results of the NRG-BN007 trial...
Bridging the Gap: Stronger Primary Care Ties May Improve Cancer Survivorship
Optimal continued care for patients with cancer may require greater involvement from primary care clinicians, according to the results of an observational study published in Current Oncology.
The study highlighted certain challenges in cancer care, including patient-centered coordination and...
EBRT With Focal Boost in Localized Prostate Cancer: 10-Year Follow-up
As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprostatic tumor in patients receiving external-beam radiotherapy (EBRT) for localized prostate cancer.
...
Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer
In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with an overall survival benefit in patients with stage III colorectal cancer aged ≤ 70 years but not in those aged > 70 ...
Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods
In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed.
...
New Drug-Releasing System Eliminates Bladder Cancer in Over 80% of Patients in a Phase II Trial
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in the phase II SunRISe-1 trial (ClinicalTrials.gov identifier NCT04640623) for individuals with high-risk non–muscle-invasive bladder cancer whose disease had previously resisted treatment. In the majority of cases, the...
Clinically Significant Fatigue and Inflammation in Breast Cancer Survivors
Clinically significant fatigue was associated with increased inflammation in breast cancer survivors, according to study findings published in BMC Women's Health. The study authors also suggested that an increase in inflammatory markers from clinical fatigue could lead to breast cancer recurrence.
...
RSNA Challenge AI Models Enhance Mammography Detection of Invasive Breast Cancer
Various artificial intelligence (AI) algorithms submitted as part of a challenge demonstrated the ability to identify different breast cancers during screening mammography, according to the results of a study published in Radiology. Ensemble models of the top submitted algorithms indicated that the ...
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
The introduction of artificial intelligence (AI) to assist colonoscopies may be linked to a reduction in the ability of endoscopists to detect adenomas in the colon without AI assistance, according to a paper published by Budzyń et al in The Lancet Gastroenterology & Hepatology.
Colonoscopy...
Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?
In a substudy of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that baseline prostate-specific membrane antigen (PSMA)–positron-emission tomography (PET) total tumor volume (TTV) was prognostic for overall survival and predictive for a beneficial effect on ...
Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy
In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estrogen receptor–positive, HER2-negative breast cancer with high-risk disease on the basis of genomic...
Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country
Remarkable advances in treatments for cancer over the past 2 decades are enabling increased personalized care for patients with the disease. However, the growing complexity of treatment methods, including targeted therapy, immunotherapy, and advanced oral therapy, make it challenging for medical...
Childhood Cancer Survivors and Long-Term Risks for Health Conditions: New Data
Some survivors of childhood cancers face a continued elevated risk of premature mortality, new cancers, chronic conditions, and other adverse health conditions as they grow older, according to new findings published in the Journal of Clinical Oncology.
An increased risk for cancer and other...
Web Tool Seeks to Reduce State Lung Cancer Mortality Rates
Experts from the National Lung Cancer Roundtable have created a customizable, web-based platform that allows groups and local leaders to develop state-based action plans for reducing lung cancer mortality rates. The platform, called the SBI Planning Tool, allows users to explore real-world...
Genomics-Guided Tool to Inform Treatment of Advanced Kidney Cancers
Results from a recent study may help to explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for patients with advanced kidney cancers. The collaborative work ...
Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach
In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...
Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD)–activating mutations, as...
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
In a cross-sectional study reported in JAMA Network Open, Abel et al found that higher rates of neoadjuvant chemotherapy (NACT) and a higher annual volume of cytoreductive surgery were associated with better survival outcomes in patients treated at Commission on Cancer–accredited cancer programs in ...
Smoking Cessation in Cancer Care: Challenges and Opportunities
Based on the results of a cohort study reported in JAMA Network Open, smoking worsened both cancer symptom burden and severity. However, Rieth et al noted that oncologic surgery may present a unique teachable moment for smoking cessation, as patients appeared to be highly motivated to quit.
The...
Survival in Older Patients With Cancer and Diabetes: GLP-1 RAs vs Other Glucose-Lowering Drugs
A retrospective cohort study published in JAMA Network Open found glucagon-like peptide-1 (GLP-1) receptor agonists to be associated with lower all-cause mortality than dipeptidyl peptidase-4 (DPP-4) inhibitors, with no significant difference from sodium-glucose cotransporter-2 (SGLT-2) inhibitors, ...
Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers
For patients with gastrointestinal (GI) cancers, chemotherapy can sometimes cause severe, even life-threatening side effects in those who carry certain genetic variants that may impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting...
Novel Single-Cell Sequencing Blood Test for Multiple Myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that may alter the diagnosis and monitoring of multiple myeloma and its precursor conditions. The new method, known as SWIFT-seq, uses single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a...
DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma
In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma...
Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS
Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...
Chemotherapy Regimens Compared in High-Grade Serous Ovarian Cancer With No BRCA Mutation
In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes of alpelisib plus olaparib vs single-agent chemotherapy in patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) with no...
Combination Therapies for Metastatic or Recurrent Pancreatic Cancer Under Study
In an interim analysis of a Japanese phase II/III trial (GENERATE, JCOG1611) reported in the Journal of Clinical Oncology, Ohba et al compared the survival benefit of mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, oxaliplatin) or S-IROX (S-1, irinotecan, oxaliplatin) vs nab-paclitaxel...
Protease Activator Approved by the FDA for Diffuse Midline Glioma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso) a protease activator, for adult and pediatric patients aged 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who have progressive disease after prior therapy. This...
RCC: Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes
Genetic testing may be the only way to differentiate between common and more rare subtypes of renal cell carcinoma (RCC) to prevent misdiagnoses, according to the results of a study published in Human Pathology.
Mucinous tubular and spindle cell carcinoma (MTSCC) was found to share many...
Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years
It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...
Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers
In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with advanced ovarian and endometrial clear cell cancers.
Study Details
Twenty-eight patients with...
Immunoglobulin Replacement Therapy and Infection Risks in CLL
Immunoglobulin replacement therapy did not lead to a reduction in the risk for serious infections leading to hospitalizations for patients with chronic lymphocytic leukemia (CLL), according to the results of a real-world Australian cohort study published in Blood Advances. This finding is at odds...
Advancing Geriatric Oncology: Where We Have Been and Where We Are Going
The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unprepared. The shortage of oncologists, along with many experienced clinicians retiring early, has...
ASCO Edge Launches for All Members
ASCO has announced the launch of ASCO Edge, an online oncology practice and operations management educational series developed by oncology professionals for oncology professionals.
ASCO Edge is a member-only benefit that will provide ASCO members with education and tools to effectively manage the ...
Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature
In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC).
Study Details
The multicenter ...
Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings
A recent study published by Menta et al in the Journal of Drugs in Dermatology found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care.
Conducted by researchers at the George Washington...
Pediatric Gliomas: Early Research on Targeted Therapies
A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common type of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and these gliomas may be sensitive to...
Outcomes Associated With COVID-19 Infection in Patients With Cancer
As reported in JAMA Oncology by Rini et al, the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) has identified outcomes associated with COVID-19 in patients with cancer.
Study Details
Between May 2020 and February 2022, the study enrolled adult patients from sites...
Prostate Cancer: One in Six Grade Group 1 Cases Linked to Higher-Risk Disease
Patients classified with "grade group 1" prostate cancer face a wide range of long-term outcomes, according to findings from a study published in JAMA Oncology. Investigators revealed that as many as one in six men with grade group 1 prostate cancers have intermediate- or high-risk disease when...
Ultraprocessed Food Consumption May Be Linked to Increased Lung Cancer Risk
Greater consumption of ultraprocessed food is associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax.
"Over the past 2 decades, the consumption of ultraprocessed food has significantly increased worldwide,...
Ayurveda in Cancer Care
Guest Editor’s Note: Ayurveda, the traditional medical system that originated in India, focuses on improving overall well-being through self-care, diet, and herbal formulations. There is a growing patient interest in using Ayurveda for symptom control and to improve quality of life. In this...
Investigating the Mechanisms of Cardiovascular Adverse Events Linked to Certain Cancer Treatments
The true upside of the many advances in cancer treatment is clear. Approximately 18.6 million people in the United States have a history of cancer, and the number of cancer survivors is expected to exceed 22 million by the year 2035.1However, one downside affecting many of these individuals is the...
Pediatric CNS Tumors: Long-Term Survival and Cure Fraction Estimates
As reported in The Lancet Oncology by Hoogendijk et al, the EUROCARE-6 population-based study has provided long-term survival rates and cure fraction estimates for pediatric patients with central nervous system (CNS) tumors across 31 European countries.
Study Details
The study involved data from...
Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the impact of the prognostic marker RUNX1::RUX1T1 fusion on the diagnosis and treatment of...
Short-Term Hormonal Treatment Offers Early Insight Into Tumor Behavior and Resistance for ER+/HER2+ Breast Cancer
How ER-positive, HER2-positive breast cancer tumors respond to a short course of hormonal treatment may help to determine whether more aggressive treatment options are necessary for each patient or not, according to translational findings published in eBioMedicine. Tumor subtype changes after 2...
Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with the FAK inhibitor defactinib in patients with recurrent low-grade serous ovarian cancer.
Study...
Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma
The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....
LLS Unveils Name Change
The Leukemia & Lymphoma Society (LLS), the global nonprofit in funding blood cancer research, patient support, and advocacy, is becoming Blood Cancer United on August 28, in advance of Blood Cancer Awareness Month in September.
For more than 75 years, LLS has been committed to reaching and...
Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC
Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible.
The guidelines, published in the journal CHEST,...
Does Preexisting Depression Impact Prostate Cancer Survival?
Based on the results of an analysis reported in JAMA Network Open by Zhang et al, preexisting depression is associated with an increased risk of mortality from prostate cancer.
The investigators commented, “Approximately one in six patients with prostate cancer experience major depression, a...
Perioperative Pembrolizumab Plus Surgery and Risk-Adapted Standard Adjuvant Therapy Shows Benefit in Locally Advanced Head and Neck Cancer
Earlier this year, the first interim analysis of the phase III KEYNOTE-689 trial showed that the use of the PD-1 inhibitor pembrolizumab as part of a perioperative treatment regimen with standard-of-care surgery plus adjuvant radiotherapy (with or without cisplatin alone) improved event-free...
Study Shows Increased Prescribing After Accelerated vs Regular Approval of Cancer Drugs
A cross-sectional study of cancer drug indications granted accelerated approval, which was published in JAMA Network Open, found that prescribing increased more after accelerated approval than after conversion to regular approval. Parikh et al also noted that off-label prescribing after accelerated ...
Pembrolizumab and De-escalation of Treatment in Resectable Cutaneous Squamous Cell Cancer
In an Australian phase II trial (De-Squamate) reported in the Journal of Clinical Oncology, Ladwa et al found that the use of pembrolizumab produced a high rate of clinical or pathologic complete response in patients with resectable cutaneous squamous cell cancer (cSCC), suggesting the potential to ...
FIGO Releases Best Practice Advice on Cancer During Pregnancy
The International Federation of Gynecology and Obstetrics (FIGO) has released a best practice guideline addressing cancer in pregnancy, a condition with limited data and complex diagnostic challenges. This new guidance—published by Nanda et al in the International Journal of Gynecology &...
Final Overall Survival Analysis in HRR-Deficient Cohort in TALAPRO-2: Addition of Talazoparib to Enzalutamide in Metastatic CRPC
As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (CRPC) cohort of the phase III TALAPRO-2 trial showed a significant benefit with the addition of talazoparib to...
Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort
As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benefit in a cohort of patients with metastatic castration-resistant prostate cancer (CRPC) unselected...
LLM Trained on Somatic Mutations Shows Prognostic and Predictive Utility
Large language models (LLMs) can be trained to understand how each patient’s somatic mutations impact their cancer prognosis and possible response to therapy, according to a presentation at the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning.
John-William...
AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis
A U.S. Food and Drug Administration (FDA)–cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective evaluation of screening digital breast tomosynthesis (DBT), findings published in Radiology showed. The...
Three in Five Liver Cancer Cases May Be Due to Preventable Risk Factors, The Lancet Commission Finds
Globally, three in five liver cancer cases may be due to preventable risk factors, and obesity-linked cases of the disease are on the rise, according to findings from The Lancet Commission on hepatocellular carcinoma. The majority of liver cancer cases could be prevented by reducing levels of viral ...
Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC
In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...
FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...
Study Finds Racial and Economic Segregation May Impact Advanced-Stage Breast and Cervical Cancer Diagnoses
Despite advances in early cancer detection, racial and ethnic minority individuals seem to be more likely to have a late-stage diagnosis of cancers that have a recommended screening. A large study by the American Cancer Society that examined the association between neighborhood-level segregation...
Esophageal Adenocarcinoma Recurrence Patterns With Perioperative Chemotherapy vs Preoperative Chemoradiotherapy
In an analysis from the German phase III ESOPEC trial reported in the Journal of Clinical Oncology, Hoeppner et al found that perioperative chemotherapy reduced distant recurrence vs preoperative chemoradiotherapy in patients with nonmetastatic esophageal adenocarcinoma.
The primary analysis of...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality, Especially for Skin and Kidney Cancers
According to the International Association of Fire & Rescue Services, there are more than 15 million firefighters protecting the inhabitants of 60 countries around the world. And while hazardous exposures from fires encountered by firefighters vary, potential risks include several known or...
Standard DNA Testing May Miss Majority of NUT Carcinomas, Study Finds
When a NUT carcinoma is detected, standard-of-care DNA next-generation sequencing (NGS) may be unable to detect upward of 75% of incidences of the disease, according to findings published in Clinical Cancer Research. The study authors suggested that to correctly detect and diagnosis NUT carcinomas, ...
STRIDE in Unresectable HCC: 5-Year Overall Survival Results From HIMALAYA
A recent exploratory analysis of the phase III HIMALAYA trial involving patients with unresectable hepatocellular carcinoma (HCC) has shown that 1 in 5 participants (19.6%) treated with the STRIDE regimen (single tremelimumab regular interval durvalumab) remained alive after 5 years of follow-up vs ...
Reevaluating Pathologic Complete Response as a Surrogate for Survival in Rectal Cancer
As reported in JAMA Network Open by Sugumar et al, a systematic review and meta-analysis of randomized clinical trials comparing neoadjuvant therapies in rectal cancer showed no trial-level association between pathologic complete response and survival.
“Our study’s findings suggest a...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Patients With Interstitial Lung Disease Face Elevated Lung Cancer Risk, Study Finds
A large prospective cohort study conducted by Ye and Kang et al and published in JAMA Network Open found that, after adjusting for familial and other cancer-related factors, interstitial lung disease (ILD) was associated with an increased risk of developing most histologic subtypes of lung cancer.
...
Intense Resistance Training for Breast Cancer Survivors With Lymphedema Risk
Resistance training can provide many benefits, including increased muscle mass; decreased adipose tissue; and improved metabolism, bone density, strength, and mobility. However, data are limited on the association between resistance training and the development or exacerbation of lymphedema, a...
Patritumab Deruxtecan Shows Efficacy in Leptomeningeal Metastases From Solid Tumors
The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a cohort of the phase II TUXEDO-3 trial. Researchers were also encouraged by the intracranial...
Realizing the Full Potential of Patient Engagement in Clinical Research
Nothing about us without us is a centuries-old value that is a cornerstone of meaningful patient engagement in clinical research. Such engagement has not been automatic and is still largely absent in geriatric oncology research, where older patients traditionally have been excluded from clinical...
Fertility Outcomes in Patients of Childbearing Potential Receiving First-Line Therapy for Advanced Lymphoma
In an analysis reported in The Lancet Oncology, Ferdinandus et al found that among patients with newly diagnosed advanced-stage classical Hodgkin lymphoma who were of childbearing potential (POCBP) in the phase III HD21 trial, those receiving BrECADD (brentuximab vedotin, etoposide,...
ASTRO Announces New President-Elect, Officers
The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors:
- Catheryn M. Yashar, MD, FASTRO, President-Elect
- Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect
- Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair ...
Noncovalent BTK Inhibitor in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In a phase III trial (BRUIN CLL-321) reported in the Journal of Clinical Oncology, Sharman et al compared treatment outcomes with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib vs investigator choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in patients ...
Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML
In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...
HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer
In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with early-stage, HER2-positive breast cancer.
Study Details
Systematic review of the literature...
Association of Type 2 Diabetes With Colorectal Cancer Risk and Survival by Tumor Immunity Status
In a German population–based, matched case-control study reported in the Journal of Clinical Oncology, Wankhede et al found that type 2 diabetes (T2D) may be associated with colorectal cancer (CRC) risk and survival according to tumor immunity status.
Study Details
The study included 1,889 CRC...
NSCLC Trial Shows Radiation May Overcome Primary Resistance to Pembrolizumab
The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in
American Cancer Society Names New CEO
The American Cancer Society (ACS) and its advocacy affiliate the American Cancer Society Cancer Action Network (ACS CAN) have announced Shane Jacobson as their Chief Executive Officer, effective August 12, 2025. He steps into the role following Wayne A.I. Frederick, MD, MBA, FACS, who has served as ...
Final Overall Survival Analysis of FLAURA2: Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC
Positive results from the final overall survival analysis of the phase III FLAURA2 trial showed that osimertinib (a third-generation, irreversible EGFR tyrosine kinase inhibitor) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically...
Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal
In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Study Details
In the...
CBO Report Finds Federal Cuts to NIH Would Threaten New Drug Development and Innovation
A new report from the nonpartisan Congressional Budget Office (CBO) has found that proposed cuts at the National Institutes of Health (NIH) could lower the number of new drugs that come to market in the next 3 decades. The report comes as Congress considers President Trump’s proposed budget for...
Biomarker Testing in Advanced Cancer: Suboptimal Rates Despite Guideline Recommendations and Growing Insurance Coverage
A retrospective cohort study reported in JAMA Network Open revealed that biomarker testing rates among patients with advanced cancer have increased over time but remain suboptimal, despite established guideline recommendations and growing insurance coverage for testing. DaCosta Byfield et al noted...
Evaluation of Racial Classification Standards in U.S. Cancer Surveillance Systems
Despite multiple federal updates to race data collection standards, researchers have found persistent discrepancies in how cancer incidence and mortality rates are recorded for racial minorities—particularly multiracial individuals. A recent study in Cancer highlights how evolving definitions of...
Breastfeeding Patterns After Treatment of Early Hormone Receptor–Positive Breast Cancer
In a prospective study (POSITIVE) reported in the Journal of Clinical Oncology, Peccatori et al investigated breastfeeding patterns among women who had a live birth after treatment of hormone receptor–positive breast cancer.
Study Details
Between December 2014 and December 2019, 518 women who...
Study Finds No Difference in Dietary Habits Between Cancer Survivors and General Population
Researchers have discovered that most cancer survivors do not make significant improvements to their diet or eating habits after their cancer diagnosis, according to findings published in Public Health Nutrition. Despite their cancer diagnosis, there was no significant difference in diet-related...
Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer.
Study Details
In the multicenter,...
Extended Follow-up for Neoadjuvant and Adjuvant Relatlimab Plus Nivolumab in Resectable Melanoma
In an extended follow-up of a phase II trial reported in the Journal of Clinical Oncology, Burton et al examined outcomes with neoadjuvant and adjuvant relatlimab-rmbw plus nivolumab in patients with resectable melanoma. Relatlimab targets LAG3, while nivolumab targets PD-1.
Study Details
In the...
Real-World Data Show COVID-19 Boosters Offer Protection for Patients With Cancer
COVID-19 vaccine boosters for adult patients with cancer helped to keep these patients from being hospitalized or admitted to intensive care units due to severe COVID-19 infections, according to the results of a retrospective cohort study published in JAMA Oncology.
“Cancer patients are a...
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes?
Aprepitant, a commonly used antiemetic, led to improvements in patient outcomes when given during chemotherapy treatment for patients with non-luminal early breast cancer. Patients showed better prognoses and survival advantages, particularly among those with triple-negative breast cancer. Study...
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
As reported in JAMA Network Open by Mamtani et al, a retrospective cohort study of patients with metastatic urothelial cancer showed population-level increases in survival after the introduction of novel cancer therapeutics—immune checkpoint inhibitors (ie, pembrolizumab and atezolizumab) and...
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
In an analysis from the French SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Taïeb et al examined survival outcomes associated with a change in ctDNA from baseline to 1 month after start of treatment in patients receiving ICI treatment with avelumab for deficient mismatch repair/microsatellite...
Classifying Pancreatic Cysts Using AI Models
In a proof-of-concept study published in the Journal of the American College of Surgeons, researchers investigated whether artificial intelligence (AI) models such as ChatGPT-4 can be used to accurately extract and classify diagnostic data from radiologic imaging reports of pancreatic cysts. The...
Outcomes Support CAR T-Cell Therapy Use in Elderly Patients With B-Cell Lymphomas
Patients in their 80s or older with B-cell lymphomas are able to receive chimeric antigen receptor (CAR) T-cell therapy safely, results of a multicenter retrospective study published in Bone Marrow Transplantation showed. These patients are usually not eligible for clinical trials of CAR T-cell...
Thyroidectomy Without Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer
In a UK phase III trial (IoN) reported in The Lancet, Mallick et al compared survival outcomes among patients with low-risk differentiated thyroid cancer who underwent thyroidectomy with no postoperative radioiodine ablation vs thyroidectomy plus ablation.
Study Details
In the multicenter...
Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945
A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...
